Abstract
Purpose
This study aims to evaluate the utility of a new technology, Lidocaine 5 % patch (L5%P), for providing analgesia without other sensory deficit in cancer patients with focal neuropathic pain (NP) related or not with cancer.
Methods
During the period February 2011 to July 2011, 83 patients were seen for the first time in our department and L5%P were prescribed to 15 of those patients (18.07 %). Information recorded in relation to the L5%P included the following: (a) Nature of NP, (b) medications tested, (c) drug combinations, (d) L5%P therapy duration, (e) efficacy, and (f) undesirable effects.
Results
Forty percent of the patients (n = 6) in our series had NP related to their cancer and 60 % (n = 9), chronic NP not related to their cancer diagnosis, but all referred to our Radiotherapy and Oncology Department for radiotherapy. The analgesic effect of the L5%P was potent in eight cases (53.33 %) and partial in four cases (26.66 %). This represents 79.99 % efficacy in selected patients. There were no serious adverse events reported in any of the patients.
Conclusion
The results indicate that there are patients with NP within a cancer setting who are suitable for treatment and successfully managed with topical L5%P, alone or in combination with other drugs.
Similar content being viewed by others
References
Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J (2008) Neuropathic pain: redefinition and grading system for clinical and research purposes. Neurology 70:1630–1635
Finnerup NB, Sindrup SH, Jensen TS (2010) Recent advances in pharmacological treatment of neuropathic pain. Med Rep 2:52–54
Cleeland CS, Farrar JT, Hausheer FH (2010) Assessment of cancer-related neuropathy and neuropathic pain. Oncologist 15(suppl 2):13–18
Caraceni A, Portenoy RK (1999) An international survey of cancer pain characteristics and syndromes. Pain 82:263–274
Fleming JA, O’Connor BD (2009) Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res Manag 15:381–388
Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM, Hanson J, Vigano A (2005) A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manag 29:224–237
Lema MJ, Foley KM, Hausherr FH (2010) Types and epidemiology of cancer-related neuropathic pain: the intersection of cancer pain and neuropathic pain. Oncologist 15(suppl 2):3–8
National Comprehensive Cancer Network (2009) NCCN clinical practice guidelines. Adult Cancer Pain 1, Available at http://www.nccn.org/professinals/physician_gls/PDF/pain.pdf. Accessed 19 Feb 2010
Urch CE, Dickenson AH (2008) Neuropathic pain in cancer. Eur J Cancer 44:1091–1096
Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH (2005) Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118:289–305
Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS (2007) Pharmacologic management of neuropathic pain: evidence based recommendations. Pain 132:237–251
Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M (2009) 5 % Lidocaine medicated plaster versus pregabalin in postherpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 25:1663–1676
Pérez C, Gálvez R, Huelbes S, Insausti J, Boyhassira D, Díaz S et al (2007) Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes 5:66
Persaud N, Strichartz GR (2002) Micromolar lidocaine selectively blocks propagating ectopic impulses at a distance from their site of origin. Pain 99:333–340
Chow E, Wu JS, Hoskin P et al (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 64:275–280
Brennan F, Carr DB, Cousins M (2007) Pain management: a fundamental human right. Anesth Analg 105:205–221
Hausherr FH, Schilsky RL, Bain S et al (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncolo 33:15–49
Jost L, Roila F (2009) ESMO guidelines working group. Management of cancer pain: ESMO clinical recommendations. Ann Oncol 20(suppl 4):170–173
Comer AM, Lamb HM (2000) Licocaine patch 5 %. Drugs 59:245–249
Campbell BJ, Rowbotham M, Davies PS, Jacob P III, Benowitz NL (2002) Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 91:1343–1350
Sinnot C (2002) Problems recruiting cancer patients to a comparative clinical trial of drug treatments for neuropathic pain in palliative care. J Pain Symptom Manag 23:270–272
Meier T, Wasner G, Faust M et al (2003) Efficacy of lidocaine patch 5 % in the treatment of focal peripheral neuropathic pain syndromes: A randomized double-blind, placebo-controlled study. Pain 106:151–158
Galer BS (2002) Effectiveness and safety of lidocaine patch 5 %. J Fam Pract 51:867–868
Nalamachu S, Crockett RS, Mathur D (2006) Lidocaine patch 5 for carpal tunnel syndrome: how it compares with injections: a pilot study. J Fam Pract 55:209–214
Kehlet H, Jensen TS, Woolf CJ (2006) Persistent postsurgical pain: risk factors and prevention. Lancet 367:1618–1625
Cheville AL, Sloan JA, Northfelt DW et al (2009) Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (NO1CB). Support Care Cancer 17:451–460
Lin PL, Fan SZ, Huang CH et al (2008) Analgesic effect of lidocaine patch 5 % in the treatment of acute herpes zoster: a double-blind and vehicle-controlled study. Reg Anesth Pain Med 33:320–325
Mackley CL, Marks JG Jr, Anderson BE (2003) Delayed-type hypersensitivity to lidocaine. Arch Dermatol 139:343–346
Conflicts of interest
The author declares that she has no conflicts of interest relating to the publication of this manuscript. She has no relationship with any organisation. No organisation has sponsored this research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
López Ramírez, E. Treatment of acute and chronic focal neuropathic pain in cancer patients with lidocaine 5 % patches. A radiation and oncology department experience. Support Care Cancer 21, 1329–1334 (2013). https://doi.org/10.1007/s00520-012-1670-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-012-1670-x